Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06281834
Other study ID # 2024P000306
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date May 2024
Est. completion date June 2027

Study information

Verified date February 2024
Source Brigham and Women's Hospital
Contact Holly Rawizza, MD, MPH
Phone 617-432-4686
Email hrawizza@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tuberculosis (TB) is the leading cause of death among children living with HIV, yet insufficient data are available on the pharmacokinetics of newer TB prevention strategies in children. Short-course TB prevention/latent TB infection (LTBI) treatment regimens increase completion rates but have not been adequately studied among children living with HIV. Our prospective, open-label PK study will examine and extend use of weekly rifapentine and isoniazid (3HP) among children receiving dolutegravir. This will address gaps in knowledge by examining two-way PK of short-course LTBI treatment in a vulnerable pediatric population.


Description:

This study is a prospective, single-arm, open-label, intensive and sparse pharmacokinetic (PK) and safety study to evaluate steady-state dolutegravir (DTG) and rifapentine (RPT) concentrations among 25 ART-naïve or experienced children living with HIV who screen negative for TB in two age categories. Study design differs by age cohort since RPT dosing is well-established for children ≥2 years of age but not for children <2 years. Children 2-11 years receive standard weekly rifapentine/isoniazid (3HP) dosing for a 12-week course, a World Health Organization (WHO)-recommended LTBI treatment option. For young children <2 years of age, intensive PK will be evaluated after a single-dose of extrapolated weekly rifapentine/isoniazid (RPT/INH), followed by standard WHO-recommended LTBI prophylaxis (isoniazid daily). Children will be recruited from two large pediatric HIV clinics in Nigeria. Children 2-11 years will receive HIV treatment that is considered standard of care consisting of weight-based DTG once daily along with two non-nucleoside reverse transcriptase inhibitors (NRTIs), plus 3HP at standard doses for LTBI treatment. Children <2 years of age also receive standard DTG-based ART as well as standard isoniazid (INH) prophylaxis for LTBI, however, they will additionally receive a single dose of weekly RPT/INH for study purposes. The primary study intervention is, therefore, additional blood sampling for drug concentration determination (both DTG and RPT) and biomarker assessment. Clinical and laboratory monitoring for toxicity occur throughout the 48 week study period. PK sampling for drug concentration determination will occur at three time points during the 48-week study. Specifically, intensive PK sampling will occur at study week 6, while sparse PK sampling will occur at weeks 4 and 7. Additionally, the endogenous biomarker of CYP3A4 activity, 4-beta-hydroxycholesterol to cholesterol ratio, will be evaluated to advance understanding of underlying mechanisms of drug action. Blood sampling to quantify this biomarker will occur at either 4 (among ART-experienced children) or 5 (ART-naive) time points during the 48-week study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date June 2027
Est. primary completion date February 2027
Accepts healthy volunteers No
Gender All
Age group 4 Weeks to 11 Years
Eligibility Inclusion Criteria: - (1) ART-naïve or ART-experienced HIV-infected children 4 weeks to <12 years of age; - (2) no evidence of active TB based on an appropriate clinical evaluation; - (3) negative TB diagnostic test if performed (other than tuberculin skin testing); - (4) weight of at least 4 kilograms; and - (5) consent of the parent or legal guardian and assent of the child (if =7 years of age). Exclusion Criteria: - (1) Baseline labs with evidence of =grade 3 abnormalities: alanine aminotransferase (ALT), total bilirubin, absolute neutrophil count (ANC), platelets, creatinine; - (2) presenting with acute respiratory distress or decompensation, or any clinical syndrome which could suggest undiagnosed TB or other opportunistic infection; or - (3) receipt of a medication that has drug-drug interactions with DTG or RPT.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rifapentine
Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children <2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
Dolutegravir
All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Brigham and Women's Hospital APIN Public Health Initiatives, University of Cape Town

Outcome

Type Measure Description Time frame Safety issue
Primary Dolutegravir AUC during weekly rifapentine/isoniazid Dolutegravir area under the concentration time curve (AUC) will be compared to therapeutic ranges established in the adult and pediatric literature. Intensive PK sampling will occur at week 6 for dolutegravir and rifapentine PK. Week 4 sparse PK sampling will provide dolutegravir exposures without rifapentine. Weeks 4 and 6
Secondary Rifapentine AUC Rifapentine AUC will be compared against adult targets. Week 7 sparse PK will provide weekly Cmin estimate. weeks 6 and 7
Secondary Proportion of participants experiencing severe (grade 3 or 4) clinical or laboratory adverse events Laboratory and clinical toxicities are monitored at 8-9 time points throughout the study and the proportion of children experiencing severe adverse events will be determined. Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT05073926 - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Not yet recruiting NCT04428294 - Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation Phase 4
Completed NCT02276755 - Vitamin D Supplementation in TB Prevention Phase 3
Withdrawn NCT03498534 - Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis Phase 4
Active, not recruiting NCT03988933 - 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB. Phase 2
Recruiting NCT06022146 - TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts Phase 3
Active, not recruiting NCT04188041 - Improving Rhode Island's Tuberculosis Preventive Services in Primary Care N/A
Recruiting NCT03730181 - Tuberculosis Clinical Trials Consortium Study 35 Phase 1/Phase 2
Completed NCT01967134 - Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis Phase 1
Completed NCT00257907 - Immune Response to Mycobacterium Tuberculosis Infection
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Active, not recruiting NCT04557176 - TB Screening Improves Preventive Therapy Uptake N/A
Completed NCT02119130 - Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa N/A
Not yet recruiting NCT02512484 - Improving the Detection of Active Tuberculosis in Accident and Emergency Departments N/A
Completed NCT00763295 - Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV? N/A
Completed NCT01850043 - The Epidemiology of TST Change in Korea N/A
Completed NCT02073669 - Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults N/A
Completed NCT02090374 - Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen N/A
Completed NCT02880982 - Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren Phase 3
Withdrawn NCT03783728 - Video Based Directly Observed Therapy for Latent TB